Neurogenic Dysphonia/Dysphagia Registry

Overview

The Neurogenic Dysphonia/Dysphagia Registry is designed to be purely observational (i.e. non-interventional, exploratory). Patient data collected from the registry is expected to be consistent with any information which can be obtained during usual care of patients with dysphonia/dysphagia treated with vocal fold augmentation.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2016

Detailed Description

The Neurogenic Dysphonia/Dysphagia Registry is a 510K post-clearance multicenter, observational, open-label registry of the benefits and risks of management and outcomes of patients with neurogenic dysphonia/dysphagia who have received vocal fold augmentation (VFA). Enrollment is open to all eligible patients meeting all of the inclusion and none of the exclusion criteria, with a target of 400 patients. Up to 100 sites in the US and abroad will be a part of the registry. Sites will provide retrospective data for active patients who have undergone VFA within the past 24 months at the site and also begin to prospectively enroll patients who are receiving VFA as a part of their usual care. Patients will be followed for up to five years prospectively, until lost to follow-up, or death.

Clinical Trial Outcome Measures

Primary Measures

  • Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.
    • Time Frame: 1 day
    • Characterize the initial assessment (e.g. types of assessments/evaluations performed and severity of voice, swallowing, cough as determined by patient reported outcomes where available)
  • Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment
    • Time Frame: 5 years
    • Characterize subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment

Secondary Measures

  • Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection
    • Time Frame: 5 years
    • Characterize voice, swallowing, and cough outcomes post-injection, as determined by patient reported outcomes (PRO) and clinician assessment, as well as select adverse events/complications of interest, associated with use of VFA products in patients with neurogenic dysphonia/dysphagia, including in patients with multiple injections
  • Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA
    • Time Frame: 5 years
    • Identify patient characteristics and medical care practices associated with improved health outcomes after VFA
  • Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection
    • Time Frame: 5 years
    • Assess and measure the duration of effect of Prolaryn products
  • Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty
    • Time Frame: 5 years
    • Describe characteristics, management, and outcomes of patients who receive CaHA implants and thyroplasty

Participating in This Clinical Trial

Inclusion Criteria

  • Males and Females, ≥18 years of age – Diagnosis of neurogenic dysphonia/dysphagia – Under active treatment with VFA and follow-up care Exclusion Criteria:

• Patients with:

  • Vocal fold scar – Laryngeal cancer defect – Irradiation to the larynx – Laryngeal trauma – End-stage cancer

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Merz North America, Inc.
  • Collaborator
    • Carelon Research
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Scott Sykes, MD, Study Director, Merz North America, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.